CoCensys was founded in 1989 with a successful IPO in 1993, it acquired ACEA Pharmaceuticals in 1994, divested its Sales and Marketing Division to Watson Pharmaceuticals in 1997, and was acquired by Purdue Pharma in 1999.
CoCensys developed allosteric modulators of the GABA-A receptor, modulators of NMDA and AMPA receptors, and sodium channel blockers with equipotent inhibitory actions at NaV1.8 and NaV1.6 isoforms. It had co-development and licensing agreements with Novartis, Parke-Davis, Searle, and Wyeth-Ayerst.
The neuroactive steroid ganaxolone, a positive allosteric modulator of GABA-A receptors, is currently in Phase 3 development by Marinus Pharmaceuticals.
Company Details
- Founded
- -
- Address
- 213 Technology Drive, Irvine,ca 92618,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://cocensys.net
- Keywords
- Pharmaceutical Manufacturing.
- HQ
- Irvine, CA
Cocensys Questions
Cocensys's website is http://cocensys.net
Cocensys's LinkedIn profile is https://www.linkedin.com/company/cocensys
Cocensys's industry is
Pharmaceutical Manufacturing
Cocensys's top competitors are
Kynexis,
Urogen Pharma,
Neurona Therapeutics,
Muna Therapeutics,
Aquestive Therapeutics,
Applied Dna Sciences,
Lachman Consultant Services,
Minerva Neurosciences.
Cocensys's categories are Pharmaceutical Manufacturing
Cocensys's founding year is 1989
